Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease prone to widespread metastatic dissemination and characterized by a desmoplastic stroma that contributes to poor outcomes. Fibroblast activation protein (FAP)-expressing Cancer-Associated Fibroblasts (CAFs) are crucial component...

Descripción completa

Detalles Bibliográficos
Autores principales: Karbhari, Aashna, Mosessian, Sherly, Trivedi, Kamaxi H., Valla, Frank, Jacobson, Mark, Truty, Mark J., Patnam, Nandakumar G., Simeone, Diane M., Zan, Elcin, Brennan, Tracy, Chen, Hongli, Kuo, Phillip H., Herrmann, Ken, Goenka, Ajit H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681241/
https://www.ncbi.nlm.nih.gov/pubmed/38011131
http://dx.doi.org/10.1371/journal.pone.0294564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681241/
https://www.ncbi.nlm.nih.gov/pubmed/38011131
http://dx.doi.org/10.1371/journal.pone.0294564

Ejemplares similares